Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHOENIX: PHP for the Treatment of Excess Nitric Oxide in Distributive Shock
2008-000504-92Phase 3Terminated
- Sponsor
- Apex Bioscience
- Start
- Oct 2008
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Vasoplegia and septic shock comparing PHP plus conventional vasopressor therapy with Placebo plus conventional vasopressor therapy (2 arms). Primary endpoint: 28-day all-cause mortality. Started Oct 2008; status: terminated.
02
Drugs
hemoximer
03
Conditions
Vasoplegiaseptic shock
Beyond the preview
Go deeper on 2008-000504-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000504-92.